At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 435 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Bimekizumab and Placebo for Chronic Plaque Psoriasis and 2 related conditions. Completed, enrolled 435 participants across 77 sites in 9 countries.
Detailed Summary
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
CountriesAustralia, Canada, Germany, Hungary, Poland, Russia, South Korea, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartFeb 2018
Primary CompletionDec 2018
Study CompletionJan 2020
TodayJul 2026
First PostedJan 25, 2018
Enrollment StartFeb 5, 2018
Primary CompletionDec 28, 2018
Study CompletionJan 7, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.4 years ago
Interventions
Bimekizumabdrug
Bimekizumab will be provided at pre-specified time intervals.
Placeboother
Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.